ArticleeLife2020
Functional interrogation of HOXA9 regulome in MLLr leukemia via reporter-based CRISPR/Cas9 screen.
Open access · goldAbstract read
In one paragraph
Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 55 citations in OpenAlex.
- Genome-wide screening identifies ZFP91 as a key regulator of EVI1 in myeloid leukemia.Oncogene · 2026Article
- Evaluating the reliability of tools for mRNA annotation and IRES studies.bioRxiv : the preprint server for biology · 2026Article
- CRISPR-Cas9 Screening and Simulated Infection Transcriptomic Identify Key Drivers of Innate Immunity in Bactrian Camels.Animals : an open access journal from MDPI · 2026Article
- Delineating transcriptomic signatures of in vitro human skeletal muscle models in comparison to in vivo references.Stem cell reports · 2025Article
- Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency.Cancer cell · 2025Article
- Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models.Science translational medicine · 2025Article
- The NUDIX hydrolase NUDT5 regulates thiopurine metabolism and cytotoxicity.The Journal of clinical investigation · 2025Article
- Genome-aware annotation of CRISPR guides validates targets in variant cell lines and enhances discovery in screens.Genome medicine · 2024Article
- Single-cell multi-modal integrative analyses highlight functional dynamic gene regulatory networks directing human cardiac development.Cell genomics · 2024Article
- Article
- CRISPR screen of venetoclax response-associated genes identifies transcription factor ZNF740 as a key functional regulator.Cell death & disease · 2024Article
- RNA-binding protein RBM5 plays an essential role in acute myeloid leukemia by activating the oncogenic protein HOXA9.Genome biology · 2024Article
- HOXA9 Regulome and Pharmacological Interventions in Leukemia.Advances in experimental medicine and biology · 2024Review
- Systematic characterization of the HOXA9 downstream targets in MLL-r leukemia by noncoding CRISPR screens.Nature communications · 2023Article
- Is HOXA5 a Novel Prognostic Biomarker for Uterine Corpus Endometrioid Adenocarcinoma?International journal of molecular sciences · 2023Article
- CRISPR screen identifies the role of RBBP8 in mediating unfolded protein response induced liver damage through regulating protein synthesis.Cell death & disease · 2023Article
- Upstream Stimulatory Factors Regulate HIV-1 Latency and Are Required for Robust T Cell Activation.Viruses · 2023Article
- Auxin-inducible degron 2 system deciphers functions of CTCF domains in transcriptional regulation.Genome biology · 2023Article
- Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: current perspectives, future challenges, and clinical implications.Frontiers in pharmacology · 2023Review
- PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia.Science advances · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Hao Zhang *Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, United States.
Yang Zhang *Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, United States.ORCID 0000-0003-1712-7211
Xinyue Zhou *Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, United States.
Shaela WrightDepartment of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, United States.
Judith HyleDepartment of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, United States.
Lianzhong ZhaoDivision of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, United States.
Jie AnDivision of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, United States.
Xujie ZhaoDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, United States.
Ying ShaoDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, United States.
Beisi XuDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, United States.ORCID 0000-0003-0099-858X
Hyeong-Min LeeDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, United States.ORCID 0000-0002-9381-3611
Taosheng ChenDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, United States.ORCID 0000-0001-6420-3809
Yang ZhouDepartment of Biomedical Engineering School of Engineering, University of Alabama at Birmingham, Birmingham, United States.
Xiang ChenDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, United States.
Rui LuDivision of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, United States.ORCID 0000-0003-1593-2612
Chunliang LiDepartment of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, United States.ORCID 0000-0002-5938-5510
St. Jude Children's Research Hospital · USUniversity of Alabama at Birmingham · US
Funding
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MMolecular Regulation of Functional Maturation in Human Direct Cardiac ReprogrammingR01HL153220 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Yang Zhou · 2020 to 2026
$2.0MAmerican Cancer Society IRG15-59-IRGNCI NIH HHS P30 CA021765NHLBI NIH HHS R01 HL153220
Abstract
Aberrant
Indexed as
CRISPR-Cas SystemsGene Expression Regulation, LeukemicAllelesCell Line, TumorCell ProliferationDown-RegulationEpigenesis, GeneticGenes, ReporterHistone-Lysine N-MethyltransferaseHomeodomain ProteinsHumansLeukemiaMyeloid-Lymphoid Leukemia ProteinUpstream Stimulatory FactorsHistone-Lysine N-Methyltransferasehomeobox protein HOXA9Homeodomain ProteinsKMT2A protein, humanMyeloid-Lymphoid Leukemia ProteinUpstream Stimulatory FactorsUSF1 protein, humanUSF2 protein, humancancer biologyCRISPR screenHOXA9humanknock-inmll-rearranged leukemiatranscriptional regulation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.